Obstructive hypertrophic cardiomyopathy (HCM) is a genetic cardiac disorder characterized by thickening of the heart muscle, leading to obstruction of blood flow and impaired cardiac function. According to Hajira Basit et al. (2024), the global prevalence of Hypertrophic Cardiomyopathy (HCM) is estimated to be around 0.2%, affecting approximately 1 in every 500 adults, as determined through echocardiographic studies. Current therapies include beta-blockers, calcium channel blockers, and novel myosin inhibitors. According to the Obstructive hypertrophic cardiomyopathy (HCM) pipeline analysis by Expert Market Research, growing research on targeted molecular therapies and gene-based treatments is expected to drive significant advancements in the treatment landscape in the coming years.
Major companies involved in the obstructive hypertrophic cardiomyopathy (HCM) pipeline analysis include Shandong Suncadia Medicine Co., Ltd., Bayer, and others.
Leading drugs currently in the pipeline include HRS-1893, BAY3723113, TN-201, and others.
Increasing R&D investments, emerging gene-targeted therapies, and expanding clinical trials are expected to drive strong pipeline growth, accelerating novel treatment options and improving disease management in the coming years.
The Obstructive Hypertrophic Cardiomyopathy (HCM) Pipeline Analysis Report by Expert Market Research gives comprehensive insights into obstructive hypertrophic cardiomyopathy (HCM) therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Obstructive Hypertrophic Cardiomyopathy (HCM). The obstructive hypertrophic cardiomyopathy (HCM) report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The obstructive hypertrophic cardiomyopathy (HCM) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with obstructive hypertrophic cardiomyopathy (HCM) treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to obstructive hypertrophic cardiomyopathy (HCM).
Read more about this report - Request a Free Sample
Obstructive hypertrophic cardiomyopathy (HCM) is a genetic heart condition characterized by abnormal thickening of the left ventricular wall, which can obstruct blood flow. It often causes shortness of breath, dizziness, fatigue, arrhythmias, and, in rare cases, sudden cardiac death. The condition arises from mutations in cardiac sarcomere protein genes, leading to abnormal contraction and impaired relaxation of the heart muscle.
Obstructive hypertrophic cardiomyopathy (HCM) treatment includes beta blockers, calcium channel blockers, and cardiac myosin inhibitors, aimed at reducing obstruction, improving blood flow, and alleviating symptoms effectively. In June 2023, Bristol Myers Squibb received European Commission approval for CAMZYOS® (mavacamten), a first-in-class cardiac myosin inhibitor in the obstructive HCM drug pipeline. Phase 3 trials EXPLORER-HCM and VALOR-HCM showed significant improvements in exercise capacity, symptom burden, and left ventricular outflow tract gradients in symptomatic adult patients.
According to Hajira Basit et al. (2024), the global prevalence of hypertrophic cardiomyopathy (HCM) is estimated at 0.2%, affecting approximately 1 in 500 adults. As per echocardiographic studies, around 25% of first-degree relatives show morphologic abnormalities. According to the American Heart Association, up to 1 in 500 young individuals in the United States may have HCM, with many remaining undiagnosed. HCM is more commonly diagnosed in males, though inheritance is autosomal dominant. These epidemiological insights are crucial for guiding the HCM drug development pipeline.
This section of the report covers the analysis of obstructive hypertrophic cardiomyopathy (HCM) drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total obstructive hypertrophic cardiomyopathy (HCM) clinical trials, with 48%, reflecting significant advanced-stage development. It is followed by phase II, which accounts for 30%, indicating strong mid-stage activity. Phase IV holds 17%, showcasing marketed and post-marketing opportunities. These balanced phase shares suggest a robust pipeline, potentially accelerating innovation and growth in the obstructive hypertrophic cardiomyopathy treatment market.
The drug molecule categories covered under the obstructive hypertrophic cardiomyopathy (HCM) pipeline analysis include small molecules, monoclonal antibodies, gene therapies, and recombinant proteins. The obstructive hypertrophic cardiomyopathy (HCM) report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for obstructive hypertrophic cardiomyopathy (HCM). In the pipeline, cardiac myosin inhibitors are emerging as a promising therapeutic class. For example, Aficamten is under investigation for its ability to reduce hypercontractility by modulating actin-myosin interactions within cardiac muscle cells. In June 2024, Northwestern University reported that clinical trials demonstrated improvements in peak oxygen uptake and symptomatic relief, positioning this drug class as a potential alternative to traditional therapies such as beta blockers and calcium channel blockers.
The EMR report for the obstructive hypertrophic cardiomyopathy (HCM) pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed obstructive hypertrophic cardiomyopathy (HCM) therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in obstructive hypertrophic cardiomyopathy (HCM) clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for obstructive hypertrophic cardiomyopathy (HCM). It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of obstructive hypertrophic cardiomyopathy (HCM) drug candidates.
HRS-1893, sponsored by Shandong Suncadia Medicine Co., Ltd., is entering a Phase III trial in patients with obstructive hypertrophic cardiomyopathy (oHCM). This highly selective small-molecule myosin inhibitor specifically targets myosin ATPase to reduce excessive myocardial contraction, decrease left ventricular hypertrophy, and improve diastolic function. The study is examining the efficacy and safety of HRS-1893 tablets compared with placebo, enrolling 216 participants, and is actively recruiting since August 2025, with completion expected by November 2026.
Aficamten, also known as BAY3723113, is being developed by Bayer to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in Japanese participants. This Phase 3 study evaluates the efficacy, safety, and tolerability of aficamten by examining heart function, symptom improvement, and quality of life. The drug works by reducing cardiac myosin activity, preventing excessive heart muscle contraction, and improving blood flow. Participants are receiving daily oral doses over a main and long-term treatment period.
TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy sponsored by Tenaya Therapeutics. The study aims to examine the safety, tolerability, pharmacodynamics, and cardiac transgene expression in adults with symptomatic MYBPC3 mutation-associated hypertrophic cardiomyopathy (HCM). TN-201 is delivering a functional MYBPC3 gene to heart muscle cells via a single intravenous infusion, aiming to restore MyBP-C protein levels and potentially halt or reverse disease progression over a five-year follow-up period.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Obstructive Hypertrophic Cardiomyopathy (HCM) Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for obstructive hypertrophic cardiomyopathy (HCM). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into obstructive hypertrophic cardiomyopathy (HCM) collaborations, regulatory environments, and potential growth opportunities.
Hypertrophic Cardiomyopathy Pipeline Analysis Report
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share